The company’s financial position saw a significant turnaround, with pro forma cash and marketable securities exceeding $310 million as of mid-2026. This liquidity provides the necessary cushion to advance its primary candidates, notably the BLA submission for the Duchenne muscular dystrophy therapy RGX-202, slated for the third quarter of this year. CEO Curran Simpson emphasized that the company is prepared to deliver on high-value catalysts, including pivotal wet AMD data expected in the final months of 2026.

Operational momentum remains high across its clinical programs. The confirmatory trial for RGX-202 met its primary endpoint with high statistical significance, and the company has already received FDA confirmation that no further studies are required for the resubmission of its Hunter syndrome treatment, NAVSUNLI. With manufacturing operations housed in-house, REGENXBIO is positioning itself to shift from clinical development toward commercial-readiness for its portfolio of rare and retinal disease therapies.